Weighted forecast
$1.94M
+11.4% against the same point last quarter. Commit is $1.22M.
Win rate
34%
Last 90 days
Avg cycle
46d
Target 40d
Slipping
5
No activity in 14 days
Qualifying
$310kProposal
$688kNegotiation
$512kClosed won
$430kHelios Biotech
Renewal at risk- Value
- $338,000
- Stage
- Proposal
- Close date
- 28 Sep 2026
- Owner
- Rae Kimura
- Source
- Conference
Health
Score 58 of 100. Logins fell 34% after the security review.
-
Proposal v3 sent, pricing adjusted for a 24-month term.
-
Security review call with their CISO and two engineers.
CRM template. Companies and figures are fictional.
Built with ux-ui-agent-skills by Thientan Soparat. All examples